Business Wire

Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease  

Del

For media excluding US/Canada and UK

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180523005102/en/

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in patients living with COPD. VESUTO® and OTIVATO® data were presented during the American Thoracic Society meeting (ATS) and PHYSACTO® data was recently published in the American Journal of Respiratory and Critical Care Medicine.1,2,3

Activity-related breathlessness is a characteristic feature of COPD.5 It limits patients’ exercise tolerance and has an impact on their daily activities, which can lead to a downward spiral of exercise avoidance and physical decline.5,6 Decreased activity results in patients experiencing further breathlessness during even lower levels of physical activity, leading to further worsening of their condition, and increasing the risk of disability and death.7 The internationally-recognised GOLD 2018 Strategy recommends maintaining or increasing physical activity for all COPD patients, regardless of disease severity.4

“It is of paramount importance that people with COPD remain as active as possible to minimise the impact of the disease on their daily lives,” said Professor Thierry Troosters, Head of the Research Group for Cardiovascular and Respiratory Rehabilitation, University of Leuven, Belgium and principal investigator for the PHYSACTO® study. “The VESUTO®, OTIVATO®, and PHYSACTO® studies collectively show how tiotropium/olodaterol, a LAMA/LABA therapy, makes it easier for people with COPD to engage in physical activity by reducing symptoms and difficulty related to physical activity, thus improving their ability to exercise.”

“Breathlessness is one of the hardest symptoms I deal with, but I try to do something active every day,” said Simon Barson, who has been living with COPD for 10 years. “Even though I get myself extremely exhausted when I cycle or walk, I do it anyway because I know I’ll get my breath back. I always feel better when I have exercised than when I have not.”

Recently presented and published study data include:

  • The VESUTO® study examined the efficacy of tiotropium/olodaterol on lung hyperinflation, exercise capacity and physical activity compared with tiotropium alone, in Japanese patients.2 In VESUTO®, tiotropium/olodaterol therapy demonstrated a significant improvement in hyperinflation compared with tiotropium, and showed a potential enhancement of exercise capacity in COPD patients.2
  • The OTIVATO® study examined the effect of tiotropium/olodaterol versus tiotropium alone on breathlessness in patients with COPD during a 3-minute constant speed shuttle test, to assess exertional breathlessness during walking.1 In OTIVATO®, tiotropium/olodaterol significantly reduced the intensity of breathlessness during walking compared to tiotropium alone.1
  • The PHYSACTO® study assessed the effects of tiotropium/olodaterol alone or in combination with 8 weeks of exercise training on exercise capacity and levels of physical activity in patients with moderate-to-severe COPD.3,8 In PHYSACTO®, tiotropium/olodaterol with or without exercise training increased exercise capacity in people with moderate to severe COPD significantly compared to those receiving placebo.3,8 A 12-week self-management behaviour modification programme was included for all four groups to provide an optimal environment for translating improvements in exercise capacity into increases in daily activity.3,8

These new data build on results from the MORACTO® and TORRACTO® 1&2 studies, and together demonstrate that tiotropium/olodaterol significantly reduces lung hyperinflation, reduces breathlessness during exercise and improves exercise endurance time enabling greater physical activity in patients living with COPD.1,2,3,9,10 The OTIVATO® and PHYSACTO® trials are part of the large-scale TOviTO® Phase III clinical trial programme investigating the efficacy and safety of tiotropium/olodaterol Respimat® in COPD.11,12,13,14,15,16,17,18,19,20

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/spiolto-respimat-enables-greater-physical-activity

Contact information

Media contact:
Boehringer Ingelheim
Corporate Communications
Media + PR
Friederike Middeke
Email: Friederike.Middeke@boehringer-ingelheim.com
Phone: +49 (6132) 77-141575
Fax: +49 (6132) 77-6601
or
Email: press@boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Saudi Arabia’s Red Sea Project on Track13.12.2018 13:49Pressemelding

A delegation from the Red Sea Development Company, led by chief executive John Pagano, was received by King Salman bin Abdulaziz at Araqa Palace in Riyadh on Tuesday (December 11). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005406/en/ King Salman bin Abdulaziz of Saudi Arabia (centre) and Crown Prince Mohammed bin Salman with John Pagano, CEO of Red Sea Development Company. [Photo courtesy Saudi Press Agency (SPA)] Mr. Pagano made a visual presentation at the palace on the master plan of the Red Sea Project, underlining its economic and development goals and the project’s objective to become a global destination for luxury tourism. Crown Prince Mohammed bin Salman, Chairman of the company, was also present. Twenty-two islands on the Red Sea will be developed as part of the project that is expected to create an estimated 70,000 jobs. It will not just contribute SAR 22 billion to Saudi Arabia’s GDP, but play a major

GSMA’s Programme ‘Tech4Girls’ Wins 2018 Corporate Citizen of the Americas Award from the Organization of American States13.12.2018 13:00Pressemelding

The Trust for the Americas has selected GSMA as a winner of the 2018 Corporate Citizen of the Americas Award in the category ‘Technical Skills for the Future of Work’ for its program ‘Tech4Girls’. The award was presented by the Secretary General of the Organization of American States (OAS), Luis Almagro, at a ceremony held last week in Washington, D.C. Ana Tavares Lattibeaudiere, Head of North America, and Paula Ferrari, Regional Marketing Director for Latin America, received the award on behalf of the GSMA. Tech4Girls is part of the global GSMA’s Women4Tech programme, which focuses on reducing the persistent gender gap in the mobile industry. Women4Tech offers different touchpoints for women across their education and career journeys through dedicated initiatives, development and networking opportunities. Women4Tech supports the United Nations Sustainable Development Goals, in particular SDG 5: “Gender Equality.” Launched in March 2018 by GSMA North America, Tech4Girls delivers hands-

FLIR Systems Launches Three Cooled Neutrino Family Thermal Camera Cores13.12.2018 13:00Pressemelding

FLIR Systems, Inc. (NASDAQ: FLIR) today announced three Neutrino™ midwave infrared (MWIR) camera cores: the small, lightweight FLIR Neutrino LC and two FLIR Neutrino Performance series cores, the SX12 and QX. The latest models expand the FLIR Neutrino cooled camera core family for commercial, industrial, and defense original equipment manufacturers (OEM) and system integrators. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005036/en/ Next generation cooled FLIR Neutrino thermal camera cores: Neutrino LC (left) and Neutrino Performance Series (right). (Photo: Business Wire) The Neutrino LC is FLIR’s first High Operating Temperature (HOT) MWIR camera core and the first model in the SWaP+C (Size, Weight, Power, and Cost) series. As the smallest, lightest weight, and lowest power consuming Neutrino model available, the LC can be integrated with smaller drones and allow drone operators to fly longer. With HOT technology, N

TYAN Introduces Entry Server Platforms Optimized for the New Intel® Xeon® E-2100 Processors13.12.2018 13:00Pressemelding

TYAN®, an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, is releasing a broad selection of new server motherboards and systems optimized for the new Intel® Xeon® E-2100 processors. The new lineup is designed to offer enhanced performance, advanced security, and reliability of cost-effective entry server solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005005/en/ TYAN's New Intel Xeon E-2100 Processor-based Platforms Increase Reliability and Security for Entry Servers. (Photo: Business Wire) “Small and medium-size businesses need to maintain their competitiveness by deploying a powerful server platform for performance, enhanced memory capabilities, and hardware-enhanced security,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “TYAN’s Intel® Xeon® E-2100 processor-based platforms are optimized for clou

Biomax Informatics launches the NeuroXM™ Brain Science Suite13.12.2018 12:57Pressemelding

Biomax Informatics AG announced the launch of its latest product, the NeuroXM™ Brain Science Suite, this week at the Biomax-ETRI Symposium on Cognitive Brain Informatics held in Planegg, Germany. Following a successful early-adaptor program, the company launched the NeuroXM suite of tools and features for working with multimodal high-dimensional brain data ready for clinical use. The award-winning NeuroXM Brain Science Suite lets brain scientists work interactively with high-dimensional multimodal brain data ranging from neuroimaging to genetics and transcriptomics. The suite includes a unified knowledge model for managing the abundant heterogeneous data available for the brain. It connects patient brain data to public knowledge in databases, atlases and ontologies for automatic annotation with methodological meta-information so that they become invaluable for clinical and scientific use. The NeuroXM suite supports every brain science task from standardizing preprocessing workflows to

Slice Insurance Cloud Services Now Available in the UK & EU13.12.2018 12:00Pressemelding

Slice Labs Inc., an award-winning on-demand insurance cloud platform provider, announced today the availability of Insurance Cloud Services (ICS) in the UK and EU. The first customer to use ICS in the UK is Legal & General with the launch of on-demand, pay-per-use homeshare cover. Insurance products available through the Slice ICS platform offer customers a rich, engaging, fully digital experience that is quick, and flexible. True to the company’s stated intention of extending global availability of ICS following a $20M USD Extended Series A, UK and EU insurers are now able to subscribe to ICS and launch on-demand insurance products customised to locale, language, and demographics. Cheryl Agius, CEO of Legal & General’s Insurance division, said “Legal & General is delighted to be working with Slice on the new on-demand product, a growing business in the US and now in the UK market.” European insurtech influencer Dr. Robin Kiera, CEO of DigitalScouting added, “Digital transformation lea